LLY vs SOPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
SOPH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a profit margin of -102.24%. While the company maintains a strong gross margin (67.39%) and healthy revenue growth (22.40%), these are overshadowed by massive operational losses and a bearish insider sentiment. The disconnect between the 'Strong Buy' analyst consensus and the deteriorating fundamental health suggests a highly speculative valuation. Overall, the company is burning capital rapidly with no clear path to profitability in the immediate term.
Compare Another Pair
Related Comparisons
LLY vs SOPH: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and SOPHiA GENETICS SA (SOPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.